Professor Chris J Packard, Professor of Vascular Biochemistry, University of Glasgow, UK, discusses clinical trial results for eicosapentaenoic acid (EPA) in lowering TG levels and considers which patients may benefit in terms of reduced risk of atherosclerotic cardiovascular disease.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
